Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Dapagliflozin 2.5mg + Glimepiride	154
Overall Study	STARTED	Dapagliflozin 5mg + Glimepiride	145
Overall Study	STARTED	Dapagliflozin 10mg + Glimepiride	151
Overall Study	STARTED	Placebo + Glimepiride	146
Overall Study	COMPLETED	Dapagliflozin 2.5mg + Glimepiride	140
Overall Study	COMPLETED	Dapagliflozin 5mg + Glimepiride	132
Overall Study	COMPLETED	Dapagliflozin 10mg + Glimepiride	141
Overall Study	COMPLETED	Placebo + Glimepiride	133
Overall Study	NOT COMPLETED	Dapagliflozin 2.5mg + Glimepiride	14
Overall Study	NOT COMPLETED	Dapagliflozin 5mg + Glimepiride	13
Overall Study	NOT COMPLETED	Dapagliflozin 10mg + Glimepiride	10
Overall Study	NOT COMPLETED	Placebo + Glimepiride	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00680745/flow